Pharmaceutical

2seventy bio completes $40m haemophilia A program deal with Novo Nordisk

US-based 2seventy bio has completed an asset purchase agreement (APA) to divest its haemophilia A candidate to Novo Nordisk.

Jun 28, 2024 - 04:00
2seventy bio completes $40m haemophilia A program deal with Novo Nordisk
US-based 2seventy bio has completed an asset purchase agreement (APA) to divest its haemophilia A candidate to Novo Nordisk.
Read the original article

Tags:

Previous Article

AI and stable funding environments are catalysts for biotech assets

Next Article

Verona scores FDA approval for Ohtuvayre as COPD maintenance therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

In N.C., Mandy Cohen built bridges to GOP. Can she find consensus as new CDC director?

In N.C., Mandy Cohen built bridges to GOP. Can she find...

Jul 14, 2023

Opinion: Fear-based messaging doesn’t stop drug use. But it does make things worse

Opinion: Fear-based messaging doesn’t stop drug use. Bu...

May 11, 2023

Elsie and GSK link to accelerate oligonucleotide discovery platform

Elsie and GSK link to accelerate oligonucleotide discov...

Jul 11, 2023